Deletion 17p: a matter of size and number?
Reads0
Chats0
About:
This article is published in Blood.The article was published on 2021-03-04 and is currently open access. It has received 1 citations till now.read more
Citations
More filters
Journal ArticleDOI
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
Wee Joo Chng,Sagar Lonial,Gareth J. Morgan,Shinsuke Iida,Philippe Moreau,Shaji Kumar,Philip Twumasi-Ankrah,Miguel Villarreal,Ajeeta B. Dash,Alexander Vorog,Xiaoquan Zhang,K. Suryanarayan,Richard Labotka,Meletios A. Dimopoulos,S. Vincent Rajkumar +14 more
TL;DR: In this article , the authors evaluated 2247 multiple myeloma patients from the TOURMALINE-MM1/-MM2/-MM3/-MM4 trials to assess the PFS benefit of ixazomib plus lenalidomide-dexamethasone (Rd) vs placebo-Rd (TOURMALINE -MM3/MM4) in specific high-risk CAs.
References
More filters
Journal ArticleDOI
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld,Hervé Avet-Loiseau,Sagar Lonial,Saad Z. Usmani,David S. Siegel,Kenneth C. Anderson,Wee Joo Chng,Philippe Moreau,Michel Attal,Robert A. Kyle,Jo Caers,Jens Hillengass,Jesús F. San Miguel,Niels W.C.J. van de Donk,Hermann Einsele,Joan Bladé,Brian G.M. Durie,Hartmut Goldschmidt,Maria-Victoria Mateos,Antonio Palumbo,Robert Z. Orlowski +20 more
TL;DR: Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-based survival and progression- free survival int( 4;14), del( 17/17 p), and t(14;16), and gain(1q).
Journal ArticleDOI
IMWG consensus on risk stratification in multiple myeloma
Wee Joo Chng,Angela Dispenzieri,C. S. Chim,R Fonseca,H. Goldschmidt,Suzanne Lentzsch,Nikhil C. Munshi,Antonio Palumbo,Jesus-Fernando San Miguel,Pieter Sonneveld,Michele Cavo,Saad Z. Usmani,Brian G.M. Durie,Hervé Avet-Loiseau +13 more
TL;DR: The International Myeloma Working Group proposes well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic Factors.
Journal ArticleDOI
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A Walker,Konstantinos Mavrommatis,Christopher P. Wardell,T. Cody Ashby,Michael A Bauer,Faith E. Davies,Adam Rosenthal,Hongwei Wang,Pingping Qu,Antje Hoering,Mehmet Kemal Samur,Fadi Towfic,Maria Ortiz,Erin Flynt,Zhinuan Yu,Zhihong Yang,Dan Rozelle,John C. Obenauer,Matthew Trotter,Daniel Auclair,Jonathan J Keats,Niccolo Bolli,Mariateresa Fulciniti,Raphael Szalat,P. Moreau,Brian G.M. Durie,A. Keith Stewart,Hartmut Goldschmidt,Marc S. Raab,Hermann Einsele,Pieter Sonneveld,Jesús F. San Miguel,Sagar Lonial,Graham Jackson,Kenneth C. Anderson,Hervé Avet-Loiseau,Nikhil C. Munshi,Anjan Thakurta,Gareth J. Morgan +38 more
TL;DR: In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, DNA drivers of aggressive clinical behavior are defined and Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.
Journal ArticleDOI
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo,Meral Beksac,Lucia Pantani,Maria Teresa Petrucci,Meletios A. Dimopoulos,Luca Dozza,Bronno van der Holt,Sonja Zweegman,Stefania Oliva,Vincent H.J. van der Velden,Elena Zamagni,Giuseppe A. Palumbo,Francesca Patriarca,Vittorio Montefusco,Monica Galli,Vladimir Maisnar,Barbara Gamberi,Markus Hansson,Angelo Belotti,Ludek Pour,Paula F. Ypma,Mariella Grasso,Alexsandra Croockewit,Stelvio Ballanti,Massimo Offidani,Iolanda Vincelli,Renato Zambello,Anna Marina Liberati,Niels Frost Andersen,Annemiek Broijl,Rossella Troia,Anna Pascarella,Giulia Benevolo,Mark-David Levin,Gerard M. J. Bos,Heinz Ludwig,Sara Aquino,Anna Maria Morelli,Ka Lung Wu,Rinske Boersma,Roman Hájek,Marc Durian,Peter A. von dem Borne,Tommaso Caravita di Toritto,Thilo Zander,Christoph Driessen,Giorgina Specchia,Anders Waage,Peter Gimsing,Ulf-Henrik Mellqvist,Marinus van Marwijk Kooy,Monique C. Minnema,Caroline Mandigers,Anna Maria Cafro,Angelo D. Palmas,Susanna Carvalho,Andrew Spencer,Mario Boccadoro,Pieter Sonneveld +58 more
TL;DR: Progressive progression-free survival was significantly improved with autologous HSCT compared with VMP and bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bORTezomIB-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.
Journal ArticleDOI
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Hervé Avet-Loiseau,Nizar J. Bahlis,Wee Joo Chng,Tamás Masszi,Luisa Viterbo,Ludek Pour,Peter Ganly,Antonio Palumbo,Michele Cavo,Christian Langer,Andrzej Pluta,Arnon Nagler,Shaji Kumar,Dina Ben-Yehuda,S. Vincent Rajkumar,Jesús F. San-Miguel,Deborah Berg,Jianchang Lin,Helgi van de Velde,Dixie Lee Esseltine,Alessandra Di Bacco,Philippe Moreau,Paul G. Richardson +22 more
TL;DR: IRd demonstrated substantial benefit compared with placebo-Rd in relapsed and/or refractory MM (RRMM) patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated withHigh- risk cytogenetic abnormalities.